Compare Garmin Ltd. (GRMN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Vertex Pharmaceuticals Incorporated — how do they compare? Garmin Ltd. trades at $271.28 (market cap $51.77B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.5× Garmin Ltd.'s market cap, and Garmin Ltd. pays a 1.56% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GRMN | VRTX | |
|---|---|---|
Market Cap | $51.77B | $128.16B |
Volume | 961,398 | 806,603 |
Sector | Technology | Health |
52-Week High | $313.16 | $557.96 |
52-Week Low | $187.10 | $407.37 |
Typical Hold Time | 83 Days | 120 Days |
Enterprise Value | $49.28B | $122.29B |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $276.16, down 1.09% today, showing strong fundamentals with consistent earnings beats and robust profitability. The company maintains impressive gross margins of 60.08% and net income margins of 24.47%, supported by steady revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent positive developments include multiple product awards and new feature rollouts across marine, fitness, and automotive segments, though technical indicators suggest near-term bearish pressure.
Garmin presents a compelling investment case with strong financial performance and analyst consensus target of $320.25 (16% upside). However, elevated valuation ratios (P/E 28.5, P/S 6.97) and technical bearish signals warrant caution. Key risks include competitive pressures in wearable technology and potential economic sensitivity in consumer discretionary spending.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
